175 related articles for article (PubMed ID: 12370067)
21. Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans-RA and can be induced through RA receptors in human breast and colon carcinoma cells.
Sonneveld E; van den Brink CE; van der Leede BM; Schulkes RK; Petkovich M; van der Burg B; van der Saag PT
Cell Growth Differ; 1998 Aug; 9(8):629-37. PubMed ID: 9716180
[TBL] [Abstract][Full Text] [Related]
22. The antiproliferative activity of all-trans-retinoic acid catabolites and isomers is differentially modulated by liarozole-fumarate in MCF-7 human breast cancer cells.
Van heusden J; Wouters W; Ramaekers FC; Krekels MD; Dillen L; Borgers M; Smets G
Br J Cancer; 1998 Apr; 77(8):1229-35. PubMed ID: 9579827
[TBL] [Abstract][Full Text] [Related]
23. Regulation of a highly specific retinoic acid-4-hydroxylase (CYP26A1) enzyme and all-trans-retinoic acid metabolism in human intestinal, liver, endothelial, and acute promyelocytic leukemia cells.
Ozpolat B; Mehta K; Lopez-Berestein G
Leuk Lymphoma; 2005 Oct; 46(10):1497-506. PubMed ID: 16194896
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates.
Gomaa MS; Lim AS; Lau SC; Watts AM; Illingworth NA; Bridgens CE; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
Bioorg Med Chem; 2012 Oct; 20(20):6080-8. PubMed ID: 22989911
[TBL] [Abstract][Full Text] [Related]
25. Role of Retinoic Acid-Metabolizing Cytochrome P450s, CYP26, in Inflammation and Cancer.
Stevison F; Jing J; Tripathy S; Isoherranen N
Adv Pharmacol; 2015; 74():373-412. PubMed ID: 26233912
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics.
Nelson CH; Buttrick BR; Isoherranen N
Curr Top Med Chem; 2013; 13(12):1402-28. PubMed ID: 23688132
[TBL] [Abstract][Full Text] [Related]
27. 3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.
Mulvihill MJ; Kan JL; Cooke A; Bhagwat S; Beck P; Bittner M; Cesario C; Keane D; Lazarescu V; Nigro A; Nillson C; Panicker B; Smith V; Srebernak M; Sun FL; O'Connor M; Russo S; Fischetti G; Vrkljan M; Winski S; Castelhano AL; Emerson D; Gibson NW
Bioorg Med Chem Lett; 2006 May; 16(10):2729-33. PubMed ID: 16504501
[TBL] [Abstract][Full Text] [Related]
28. P450-dependent enzymes as targets for prostate cancer therapy.
De Coster R; Wouters W; Bruynseels J
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
[TBL] [Abstract][Full Text] [Related]
29. Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold.
Gomaa MS; Bridgens CE; Illingworth NA; Veal GJ; Redfern CP; Brancale A; Armstrong JL; Simons C
Bioorg Med Chem; 2012 Jul; 20(14):4201-7. PubMed ID: 22727372
[TBL] [Abstract][Full Text] [Related]
30. Altered metabolism of all-trans-retinoic acid in liposome-encapsulated form.
Parthasarathy R; Mehta K
Cancer Lett; 1998 Dec; 134(2):121-8. PubMed ID: 10025871
[TBL] [Abstract][Full Text] [Related]
31. Physiologically Based Pharmacokinetic Model of All-
Jing J; Nelson C; Paik J; Shirasaka Y; Amory JK; Isoherranen N
J Pharmacol Exp Ther; 2017 May; 361(2):246-258. PubMed ID: 28275201
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of the
Stevison F; Hogarth C; Tripathy S; Kent T; Isoherranen N
Drug Metab Dispos; 2017 Jul; 45(7):846-854. PubMed ID: 28446509
[No Abstract] [Full Text] [Related]
33. Substrate specificity and ligand interactions of CYP26A1, the human liver retinoic acid hydroxylase.
Thatcher JE; Buttrick B; Shaffer SA; Shimshoni JA; Goodlett DR; Nelson WL; Isoherranen N
Mol Pharmacol; 2011 Aug; 80(2):228-39. PubMed ID: 21521770
[TBL] [Abstract][Full Text] [Related]
34. Study on cytochrome p-450 dependent retinoic Acid metabolism and its inhibitors as potential agents for cancer therapy.
Ahmad M
Sci Pharm; 2011; 79(4):921-35. PubMed ID: 22145115
[TBL] [Abstract][Full Text] [Related]
35. Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).
Mulvihill MJ; Kan JL; Beck P; Bittner M; Cesario C; Cooke A; Keane DM; Nigro AI; Nillson C; Smith V; Srebernak M; Sun FL; Vrkljan M; Winski SL; Castelhano AL; Emerson D; Gibson N
Bioorg Med Chem Lett; 2005 Mar; 15(6):1669-73. PubMed ID: 15745819
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of all-TRANS-retinoic acid metabolism by R116010 induces antitumour activity.
Van Heusden J; Van Ginckel R; Bruwiere H; Moelans P; Janssen B; Floren W; van der Leede BJ; van Dun J; Sanz G; Venet M; Dillen L; Van Hove C; Willemsens G; Janicot M; Wouters W
Br J Cancer; 2002 Feb; 86(4):605-11. PubMed ID: 11870544
[TBL] [Abstract][Full Text] [Related]
37. Metabolism of retinoic acid: implications for development and cancer.
Sonneveld E; van der Saag PT
Int J Vitam Nutr Res; 1998; 68(6):404-10. PubMed ID: 9857269
[TBL] [Abstract][Full Text] [Related]
38. Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice.
Huynh CK; Brodie AM; Njar VC
Br J Cancer; 2006 Feb; 94(4):513-23. PubMed ID: 16449997
[TBL] [Abstract][Full Text] [Related]
39. Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites.
Marill J; Cresteil T; Lanotte M; Chabot GG
Mol Pharmacol; 2000 Dec; 58(6):1341-8. PubMed ID: 11093772
[TBL] [Abstract][Full Text] [Related]
40. The cloning and characterization of a novel cytochrome P450 family, CYP26, with specificity toward retinoic acid.
Haque M; Anreola F
Nutr Rev; 1998 Mar; 56(3):84-5. PubMed ID: 9564181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
